Form 4: Oragenics Director Converts Preferred Stock to Common Shares

Director Robert Koski converted 1,500,000 shares of Series B Convertible Preferred Stock into 5,000 shares of common stock.

Summary

• Robert Koski, a director at Oragenics Inc., converted 1,500,000 shares of Series B Convertible Preferred Stock into 5,000 shares of common stock on December 11, 2024.
• The conversion was executed by the Koski Family Limited Partnership (KFLP), of which Mr. Koski is a general partner.
• Following the transaction, Mr. Koski directly owns 27,940 shares of common stock and indirectly owns 23,367 shares through KFLP.
• The Series B preferred stock was originally issued on November 8, 2017, at $0.50 per share and had no expiration date.
• Due to reverse stock splits, the adjusted conversion price was $300.00 per share.

Sentiment

Score: 5

Explanation: The document is a routine filing of a stock conversion by a director, which is neither positive nor negative for the company's outlook.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders reporting changes in their beneficial ownership of company stock. It does not indicate any specific industry trend but rather a routine transaction by a company director.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The conversion of preferred stock to common stock is a common transaction, especially when preferred stock has conversion rights.
• The reverse stock splits are not uncommon for companies with low share prices, and the adjusted conversion price reflects these splits.

Stakeholder Impact

• The conversion of preferred stock to common stock may slightly increase the number of common shares outstanding, but the impact is likely minimal.

Key Dates

Keywords

Oragenics, Robert Koski, Series B Convertible Preferred Stock, Common Stock, Stock Conversion, Director Ownership, KFLP